CR8275A - 2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS - Google Patents

2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS

Info

Publication number
CR8275A
CR8275A CR8275A CR8275A CR8275A CR 8275 A CR8275 A CR 8275A CR 8275 A CR8275 A CR 8275A CR 8275 A CR8275 A CR 8275A CR 8275 A CR8275 A CR 8275A
Authority
CR
Costa Rica
Prior art keywords
carbonilamino
replaced
piperidinaminopiridinas
piperidinaminobenzenos
ht1f agonists
Prior art date
Application number
CR8275A
Other languages
English (en)
Inventor
Jesus Blanco Pillado Maria
Philip Cohen Michael
Ann Filla Sandra
John Hudziak Kevin
Timothy Colman Daniel
Rae Benesh Dana
Victor Frantz
Xu Yao-Chang
Ping Ying Bai
Piattzacherl Deanna
Zhang Deyi
Michael Mathes Brian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR8275A publication Critical patent/CR8275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona a compuestos de la formula I: o una adicion de sal de acido farmaceuticamente aceptable de la misma, donde; X es -C(R3c)=-N=.
CR8275A 2003-09-12 2006-03-03 2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS CR8275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50278003P 2003-09-12 2003-09-12

Publications (1)

Publication Number Publication Date
CR8275A true CR8275A (es) 2006-06-06

Family

ID=34434850

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8275A CR8275A (es) 2003-09-12 2006-03-03 2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS

Country Status (30)

Country Link
US (3) US7291632B2 (es)
EP (1) EP1663971B1 (es)
JP (1) JP4700614B2 (es)
KR (1) KR100777875B1 (es)
CN (1) CN1849307B (es)
AR (1) AR045619A1 (es)
AT (1) ATE538093T1 (es)
AU (1) AU2004280320B2 (es)
BR (1) BRPI0414241A (es)
CA (1) CA2537936C (es)
CR (1) CR8275A (es)
CY (1) CY1112475T1 (es)
DK (1) DK1663971T3 (es)
EA (1) EA011274B1 (es)
EC (1) ECSP066415A (es)
ES (1) ES2379665T3 (es)
IL (1) IL173521A (es)
MA (1) MA28212A1 (es)
MX (1) MXPA06002767A (es)
MY (1) MY144623A (es)
NO (1) NO20061584L (es)
NZ (1) NZ545049A (es)
PE (1) PE20050350A1 (es)
PL (1) PL1663971T3 (es)
PT (1) PT1663971E (es)
SI (1) SI1663971T1 (es)
TW (1) TWI340740B (es)
UA (1) UA82711C2 (es)
WO (1) WO2005035499A1 (es)
ZA (1) ZA200602072B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
DE102005055892A1 (de) * 2005-11-22 2007-05-24 Henkel Kgaa Neue Kupplerkomponenten
CA2757019C (en) * 2009-04-02 2018-05-15 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
KR20120069710A (ko) * 2009-09-08 2012-06-28 교린 세이야꾸 가부시키 가이샤 ４?(５?메틸피리딘?２?일아미노)피페리딘?１?카복실산 유도체의 제조방법
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
US20160168132A1 (en) * 2013-07-31 2016-06-16 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
CN109596521A (zh) * 2018-02-11 2019-04-09 中国科学院海洋研究所 磷钼蓝分光光度法中还原剂的保存方法
US11858910B2 (en) 2018-08-24 2024-01-02 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
CN110845402B (zh) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 吡啶亚甲基哌嗪衍生物及其用途
WO2021097781A1 (zh) * 2019-11-22 2021-05-27 广东东阳光药业有限公司 吡啶亚甲基哌啶衍生物及其用途
CN113045540B (zh) * 2019-12-27 2024-02-13 上海天慈国际药业有限公司 一种拉司米地坦的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
DE4320484A1 (de) * 1993-06-21 1994-12-22 Dornier Gmbh Steuerbares Supraleiter-Bauelement
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CZ288897A3 (cs) 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
CA2234166A1 (en) 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
CA2264267A1 (en) 1996-08-28 1998-03-05 Michael Edward Flaugh Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta¬b|benzofurans
JP2001501946A (ja) * 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
ATE252572T1 (de) 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
WO2000034266A1 (en) 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
KR20010102003A (ko) 1999-02-10 2001-11-15 피터 지. 스트링거 5-ｈｔ1ｆ 효능제
DE60008073T2 (de) 1999-02-26 2004-08-05 Eli Lilly And Co., Indianapolis Furo[3,2-b]pyridine als 5-ht1f agonisten
AU2001241128A1 (en) * 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
CN1777584A (zh) * 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists

Also Published As

Publication number Publication date
EA011274B1 (ru) 2009-02-27
AR045619A1 (es) 2005-11-02
CA2537936C (en) 2013-03-12
PE20050350A1 (es) 2005-05-17
US7291632B2 (en) 2007-11-06
JP2007505105A (ja) 2007-03-08
EP1663971B1 (en) 2011-12-21
ES2379665T3 (es) 2012-04-30
MA28212A1 (fr) 2006-10-02
NO20061584L (no) 2006-06-06
PT1663971E (pt) 2012-03-21
UA82711C2 (en) 2008-05-12
TW200521113A (en) 2005-07-01
US7803813B2 (en) 2010-09-28
NZ545049A (en) 2009-06-26
IL173521A (en) 2012-10-31
KR100777875B1 (ko) 2007-11-28
MY144623A (en) 2011-10-14
AU2004280320A1 (en) 2005-04-21
EA200600570A1 (ru) 2006-12-29
BRPI0414241A (pt) 2006-11-07
SI1663971T1 (sl) 2012-05-31
US20070270466A1 (en) 2007-11-22
CA2537936A1 (en) 2005-04-21
JP4700614B2 (ja) 2011-06-15
US20110034511A1 (en) 2011-02-10
US20060287363A1 (en) 2006-12-21
MXPA06002767A (es) 2006-06-14
CY1112475T1 (el) 2015-12-09
CN1849307A (zh) 2006-10-18
EP1663971A1 (en) 2006-06-07
WO2005035499A1 (en) 2005-04-21
AU2004280320B2 (en) 2010-02-18
ATE538093T1 (de) 2012-01-15
ZA200602072B (en) 2007-09-26
DK1663971T3 (da) 2012-03-19
IL173521A0 (en) 2006-07-05
KR20060087554A (ko) 2006-08-02
TWI340740B (en) 2011-04-21
ECSP066415A (es) 2006-09-18
CN1849307B (zh) 2011-08-03
PL1663971T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
CR8275A (es) 2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS
TW200728307A (en) Novel spirochromanone derivatives
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
NO20062644L (no) DPP-IV inhibitorer
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
HRP20120323T1 (en) Diarylhydantoin compounds
PA8523001A1 (es) Derivados de la 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de glicogeno sintasa quinasa-3b
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
TNSN06338A1 (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
WO2004035569A3 (de) Neue verbindungen mit antibakterieller aktivität
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
GT200100148A (es) Derivados de 4-fenil-piridina.
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
SI1970372T1 (sl) Soli 9-oksoakridin-10-ocetne kisline z 1-alkilamino-1-deoksi-polioli
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
GB0212410D0 (en) Organic compounds
WO2007000655A3 (en) Novel pyrazolopyrimidinone derivatives
DE60216948D1 (en) 4&#39;-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
CR8456A (es) Inhibidores heterociclil amino de 11- beta- hidroxiesteroide deshidrogenasa tipo 1